Payment overview · 2025
General Payments
$785.29
9 reported records · 7 companies
Healthcare provider profile · identity verified
Thaeer Sawa, MD
Allopathic & Osteopathic Physicians|General Practice · STERLING HEIGHTS, MI · NPI 1093109241
Verified facts
What the public records show
CMS Open Payments records show Thaeer Sawa, MD received $785.29 in general payments during 2025 across 9 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 308 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 308 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $165.84 | 21.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.74 | 15.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.74 | 15.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $122.76 | 15.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $119.93 | 15.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $107.10 | 13.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.18 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $785.29 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $165.84 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $122.76 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $107.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 308 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
308 | 49 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
308 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
149 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 691 | 122 |
| Metformin Hcl | Metformin Hcl | 328 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 318 | 58 |
| Jardiance | Empagliflozin | 308 | 49 |
| Famotidine | Famotidine | 264 | 45 |
| Linzess | Linaclotide | 235 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 225 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 220 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 218 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 31 |
| Omeprazole | Omeprazole | 198 | 49 |
| Furosemide | Furosemide | 181 | 31 |
| Losartan Potassium | Losartan Potassium | 178 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 36 |
| Lisinopril | Lisinopril | 163 | 32 |
| Azithromycin | Azithromycin | 155 | 85 |
| Trulicity | Dulaglutide | 149 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 21 |
| Ketoconazole | Ketoconazole | 127 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 23 |
| Eliquis | Apixaban | 108 | 16 |
| Allopurinol | Allopurinol | 104 | 16 |
| Donepezil Hcl | Donepezil Hcl | 102 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 15 |
| Gabapentin | Gabapentin | 99 | 23 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 98 | 19 |
| Alendronate Sodium | Alendronate Sodium | 97 | 19 |
| Potassium Chloride | Potassium Chloride | 97 | 15 |
| Carvedilol | Carvedilol | 94 | 16 |
| Vascepa | Icosapent Ethyl | 88 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 23 |
| Montelukast Sodium | Montelukast Sodium | 83 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 79 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 79 | 48 |
| Hydrocortisone | Hydrocortisone | 78 | 20 |
| Tramadol Hcl | Tramadol Hcl | 77 | 22 |
| Simvastatin | Simvastatin | 75 | 15 |
| Januvia | Sitagliptin Phosphate | 70 | 11 |
| Amoxicillin | Amoxicillin | 64 | 37 |
| Atenolol | Atenolol | 64 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 62 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 61 | 20 |
| Repaglinide | Repaglinide | 61 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 60 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | 12 |
| Pregabalin | Pregabalin | 57 | 11 |
| Tradjenta | Linagliptin | 57 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | suppressed |
| Finasteride | Finasteride | 55 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 55 | 37 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 11 |
| Ibuprofen | Ibuprofen | 51 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Novolog Flexpen | Insulin Aspart | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 44 | suppressed |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Prolia | Denosumab | 39 | 22 |
| Meloxicam | Meloxicam | 37 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 17 |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | suppressed |
| Mupirocin | Mupirocin | 33 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 15 |
| Naproxen | Naproxen | 31 | 11 |
| Valsartan | Valsartan | 31 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 26 |
| Loperamide | Loperamide Hcl | 27 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | 13 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Procto-Med Hc | Hydrocortisone | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 21 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 15 |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 15 |
| Baclofen | Baclofen | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $785.29 · 9 records | Boehringer Ingelheim Pharmaceuticals, Inc. | BREZTRI, Cologuard Collection Kit, JARDIANCE, REXULTI, VOQUEZNA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error